Clinical ophthalmology (Auckland, N.Z.)最新文献

{"title":"Erratum: Determinants of Healthcare Professionals' Knowledge on Age-Related Macular Degeneration Risk Factors in Ethiopia [Corrigendum].","authors":"","doi":"10.2147/OPTH.S562800","DOIUrl":"10.2147/OPTH.S562800","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.2147/OPTH.S514480.].</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3009-3010"},"PeriodicalIF":0.0,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12403023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, Incidence, and Treatment Characteristics of Primary Open-Angle Glaucoma Among Medicare Fee-for-Service Beneficiaries.","authors":"Jonathan S Myers, Elizabeth A Donckels, Tigwa H Davis, Scott B Robinson, Zulkarnain Pulungan, Teresa L Brevetti, Joel Fain, Abhishek A Nair","doi":"10.2147/OPTH.S536664","DOIUrl":"10.2147/OPTH.S536664","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to describe Medicare FFS beneficiaries with prevalent and incident POAG, and to determine their demographic characteristics. Secondary objectives included describing POAG prescription rates, prescribers of POAG therapy, and dry eye disease rates among POAG prevalent beneficiaries.</p><p><strong>Patients and methods: </strong>The study was a retrospective cohort analysis using de-identified Medicare FFS medical and pharmacy claims and enrollment data (Parts A/B/D) spanning from January 1, 2016, to December 31, 2021. Medicare FFS beneficiaries were included in the analysis if they were diagnosed or treated for POAG, 65 years of age or older, and continuously enrolled for at least 24 months. Beneficiaries were identified between January 1, 2017, and December 31, 2021, allowing for a 12-month baseline to categorize patients as incident or prevalent. Comorbid dry eye disease and prescription POAG therapies were also identified. Prescriber NPIs were used to classify prescriber types.</p><p><strong>Results: </strong>From 2017 to 2021, 5.5-6.2% of Medicare FFS beneficiaries were identified with prevalent POAG, with ~1% categorized as incident. A higher proportion of POAG beneficiaries were older and/or Black. At least 81% received POAG prescription therapy each year, with ophthalmologists as most frequent prescribers. Comorbid dry eye was documented in 16.4-18.7% of beneficiaries with prevalent POAG, and in 11.8-13.6% of beneficiaries with incident POAG.</p><p><strong>Conclusion: </strong>A significant proportion of Medicare FFS beneficiaries have POAG. While most people with POAG received some type of prescription therapy each year, a notable proportion of individuals had no form of prescription POAG therapy identified. Given higher rates of dry eye disease in people with glaucoma, dry eye disease screening and care among beneficiaries with POAG should be promoted. Future research should evaluate treatment patterns and outcomes among Medicare FFS beneficiaries with comorbid POAG and dry eye disease.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3019-3031"},"PeriodicalIF":0.0,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12401664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"VISULYZE-Generated Nomogram-Assisted KLEx for Myopia and Astigmatism Correction: 3-Month Follow-Up Results.","authors":"Qi Wan, Ran Wei, Jing Tang, Ying-Ping Deng, Ke Ma","doi":"10.2147/OPTH.S551923","DOIUrl":"10.2147/OPTH.S551923","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the efficacy, safety, and predictability of Keratorefractive Lenticule Extraction (KLEx) surgery guided by a VISULYZE-generated nomogram for myopia and astigmatism correction.</p><p><strong>Methods: </strong>This prospective cohort study included 130 consecutive patients (260 eyes) undergoing KLEx surgery using a VISULYZE-generated nomogram. Patients were followed for 3 months postoperatively. The primary outcome measures were uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), and spherical equivalent (SE). \"Nine Standard Graphs\" were generated using VISULYZE software and analyzed according to international standards for evaluating the quality of corneal refractive surgery. Subgroup analyses based on age (≤30 years vs >30 years) and preoperative SE (≤-6.00 D vs >-6.00 D) were performed.</p><p><strong>Results: </strong>At 3 months postoperatively, 96% of eyes achieved UDVA of 20/20 or better, and 96.2% maintained or improved CDVA compared to preoperatively. No eyes lost 1 or more lines of CDVA. The correlation coefficient (R²) between attempted and achieved SE was 0.9732. 98.1% of eyes were within ±0.50 D of the attempted SE. 99.2% of eyes achieved a postoperative cylinder ≤0.50 D. Subgroup analysis revealed that older patients (>30 years) had slightly lower UDVA compared to younger patients, while high myopes (≤-6.00 D) showed a trend towards slight under-correction and lower efficacy compared to moderate and low myopes. However, astigmatism correction was comparable between subgroups.</p><p><strong>Conclusion: </strong>KLEx surgery guided by a VISULYZE-generated nomogram demonstrates excellent efficacy, safety, and predictability for myopia and astigmatism correction. While age and preoperative myopia degree may subtly influence efficacy, the nomogram provides a valuable tool for personalized surgical planning. Further research is warranted to refine nomogram development, particularly for older and highly myopic patients.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2985-2995"},"PeriodicalIF":0.0,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic Deficiencies in the Vitreous of Diabetic Retinopathy: Exploring the Potential of Dietary Supplementation to Address Key Metabolite Imbalances.","authors":"John Kim Hiller, Elise Sandås Sand, Helge Rootwelt, Anja Østeby Vassli, Xhevat Lumi, Morten Carstens Moe, Tor Paaske Utheim, Katja Benedikte Prestø Elgstøen, Goran Petrovski","doi":"10.2147/OPTH.S531638","DOIUrl":"10.2147/OPTH.S531638","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate the metabolic alterations in the vitreous humor of patients with diabetes across different stages of diabetic retinopathy (DR) and explore potential dietary interventions to mitigate these changes.</p><p><strong>Patients and methods: </strong>Vitreous samples were collected from 23 patients undergoing vitrectomy and grouped into controls, diabetic without DR, non-proliferative DR (NPDR), and proliferative DR (PDR). Metabolomic analysis was performed using mass spectrometry, focusing on identifying significantly altered metabolites.</p><p><strong>Results: </strong>A total of 82 features were identified, of which several were significantly reduced in DR compared to controls. Ascorbate and taurine were notably lower in NPDR (<i>p</i> < 0.01), while choline and N-acetylaspartic acid were significantly reduced in NPDR and PDR (<i>p</i> < 0.01). Tagatose was significantly reduced in PDR (<i>p</i> < 0.05), while stachydrine and serine displayed biphasic trends, decreasing in NPDR (<i>p</i> < 0.001; <i>p</i> < 0.05) but increasing in PDR (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>The results suggest that key metabolites involved in antioxidant defense, membrane integrity, and neuronal function are disrupted in the vitreous humor of patients with DR. Dietary supplementation targeting these metabolic deficiencies, such as increased intake of ascorbate, taurine, serine, choline, and stachydrine, may offer adjunctive support in managing DR progression.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2997-3007"},"PeriodicalIF":0.0,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular Surface Alteration on Corneal Endothelial Decompensation and Descemet's Membrane Endothelial Keratoplasty.","authors":"Minglu Ma, Xiaojuan Dong, Jing Wu, Jiayin Peng, Ruilin Guo, Yi Yu, Chenjia Xu, Chen Ouyang, Ting Huang","doi":"10.2147/OPTH.S508390","DOIUrl":"10.2147/OPTH.S508390","url":null,"abstract":"<p><strong>Objective: </strong>To explore alterations in tears and ocular surface throughout Descemet's Membrane Endothelial Keratoplasty (DMEK), thereby offering valuable insights for clinical intervention.</p><p><strong>Methods: </strong>This study was conducted on 84 patients (84 eyes) with CED and received DMEK who visited the Zhongshan Ophthalmic Center of Sun Yat-sen University from April 2022 to January 2024. All patients were evaluated preoperatively and 1, 3, 6, and 12 months postoperatively, with 31 patients (31 eyes) post-24 months above. This cohort was then compared against a normal control of 21 individuals (21 eyes). Main clinical outcomes included lipid layer thickness (LLT), blink counts and partial blink rate (PBR) measured by Lipiview interferometer, in vivo confocal microscopy (IVCM) was used to detect the density of epithelial wing cells, leukocytes, subbasal dendritic cells (DCs) and endothelial cells.</p><p><strong>Results: </strong>Compared with normal control, LLT was decreased at 6 months (P = 0.053); total blink counts were significantly higher at 36 months (P < 0.05) after DMEK, while LLT was significantly lower (P < 0.05). Utilizing IVCM, an increased leukocytes density was identified in CED patients, which correlated positively with Log MAR visual acuity (r = 0.261, P = 0.04) and inversely with epithelial wing cells density (r = -0.319, P = 0.009). Leukocytes density decreased to comparable level at postoperative 3 months (P = 0.11). Subbasal DCs density was still higher at 6 months postoperatively (P < 0.05), while there was no difference at 12 months after DMEK (P > 0.05).</p><p><strong>Conclusion: </strong>Abnormalities of LLT can occur at different stages after DMEK. Besides, the immune reaction on cornea is still active within 6 months after DMEK.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2977-2984"},"PeriodicalIF":0.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravitreal Double-Dose Conbercept Injection for the Treatment of Neovascular Age-Related Macular Degeneration: A Pilot Real-Life Clinical Practice Study.","authors":"Tianwei Qian, Yanping Zhou, Hao Zhou, Wenshu Wu, Yuanzhi Yuan, Suqin Yu, Xun Xu","doi":"10.2147/OPTH.S540363","DOIUrl":"10.2147/OPTH.S540363","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the efficacy and safety of conbercept for neovascular age-related macular degeneration (nAMD) when administered at the labeled dose (0.5 mg) and double dose (1.0 mg).</p><p><strong>Methods: </strong>Patients with nAMD were randomized to either 1.0 mg or 0.5 mg groups. The 1.0 mg group received intravitreal injection of 1.0 mg conbercept once monthly for the first three months, followed by a pro re nata regimen (3+PRN). The 0.5 mg group received 3+PRN regimens of intravitreal 0.5 mg conbercept throughout the treatment period. Changes in best corrected visual acuity (BCVA), central macular thickness (CMT), and maximum pigment epithelial detachment (PED) height from baseline were compared between the two treatment groups at 1-, 3-, 6-, and 12-month follow-ups.</p><p><strong>Results: </strong>Thirty-three patients completed the study, including 16 in the 0.5 mg group with an average age of 74.00 ± 8.23 years, and 17 in the 1.0 mg group with an average age of 72.29 ± 6.47 years. At 3-month, BCVA improvement in the 1.0 mg group was significantly higher than in the 0.5 mg group (<i>P</i> = 0.0450), though no differences were observed at other time points. There was no statistical difference in CMT reduction at any follow-up points. Regarding PED height reduction, a significant difference was observed at the 1-month follow-up (<i>P</i> = 0.0345), but not at the 3-, 6-, or 12-month follow-ups. After drying the macula, the recurrence interval of fluid in the 1.0 mg group was significantly longer than in the 0.5 mg group (<i>P</i> = 0.0360). No related adverse event was reported in either group.</p><p><strong>Conclusion: </strong>While the 1.0 mg group showed a transient but significant BCVA improvement at 3 months and a longer recurrence interval, further large-scale trials are needed to validate these preliminary findings.</p><p><strong>Trial registration: </strong>This study was registered with the Chinese Clinical Trial Registry (http://www.chictr.org.cn/, ChiCTR2000029503). Registration date: 03/02/2020.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2965-2976"},"PeriodicalIF":0.0,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Regimens with Ranibizumab in Neovascular Age-Related Macular Degeneration: Real-World Results from the PACIFIC Study.","authors":"Katrin Lorenz, Christos Haritoglou, Daniel Barthelmes, Armin Mir Mohi Sefat, Hüsnü Berk, Erik Beeke, Martin Scheffler, Matthias Iwersen, Bettina Müller, Focke Ziemssen","doi":"10.2147/OPTH.S512630","DOIUrl":"10.2147/OPTH.S512630","url":null,"abstract":"<p><strong>Introduction: </strong>Intravitreal anti-VEGF is the gold standard for treating neovascular age-related macular degeneration (nAMD). The treatment success depends not only on drug efficacy but also on regimen feasibility for physicians and patients. The implementation of different regimen might lead to varying outcomes. \"Treat-and-extend\" aims to minimize undertreatment with injections at each visit and tailored intervals. This study investigates the utilization and effectiveness of ranibizumab in nAMD, focusing on different treatment regimens in real-world settings.</p><p><strong>Materials and methods: </strong>The PACIFIC study, a non-interventional, prospective, multicenter study, included nAMD patients treated with ranibizumab at 185 sites across Germany, the Netherlands and Switzerland. Over 24 months, functional and morphological outcomes were documented for 3051 patients over 24 months, highlighting the practiced treatment regimens.</p><p><strong>Results: </strong>A pattern of an observational approach with nevertheless increasing interval extension prevailed (70.4%, 1028 pre-treated; 68.6%, 1090 treatment-naïve patients), emerging as the preferred strategy within the first 3 months. Across all regimens, the average number of injections was comparable (mean ± SD: 7.34 ± 5.30 in pre-treated; 7.26 ± 4.70 in treatment-naïve patients). The treat and extend regimen, however, demonstrated superior effectiveness in improving visual acuity, particularly among treatment-naïve patients (number of injections: 7.89 ± 5.54 pre-treated; 9.54 ± 5.42 treatment-naïve patients).</p><p><strong>Conclusion: </strong>Over 2-year observational period, the treat and extend regimen emerged as a highly effective approach, particularly for those newly diagnosed, with a low risk of undertreatment. Despite its benefits, an unconscious shift to a observe-and-extend or \"monitor-and-extend\" approach occurred early in treatment, highlighting the need for tailored approaches to optimize patient outcomes in clinical practice.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2927-2937"},"PeriodicalIF":0.0,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12394746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Visual Outcomes and Rotational Stability of a Monofocal Toric Intraocular Lens.","authors":"Ben LaHood, Rachael C Peterson","doi":"10.2147/OPTH.S532933","DOIUrl":"10.2147/OPTH.S532933","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the real-world distance and intermediate visual outcomes, rotational stability, and adverse events (AEs) of patients implanted with a Clareon aspheric monofocal toric intraocular lens (IOL) preloaded in the AutonoMe delivery system (Alcon, USA; models CNA0T2 to CNA0T6) up to one-month postoperative.</p><p><strong>Methods: </strong>Surgical charts from January 2021 to October 2023 were reviewed for adult patients (≥18 years) who previously received a CNA0T2 to CNA0T6 (T2 to T6) IOL during uneventful cataract surgery and were targeted for emmetropia/first minus. Overall, charts from 193 eyes of 121 patients were screened, with 161 eyes of 107 patients included in the study. Data were collected from preoperative, and postoperative records up to approximately one-month (4-5 weeks), and included monocular corrected distance visual acuity (CDVA), uncorrected and distance-corrected intermediate visual acuity (UIVA and DCIVA), residual astigmatism, and absolute IOL rotation (measured from the axis position at the end of surgery up to one-month).</p><p><strong>Results: </strong>For the full cohort (T2 to T6 IOLs, n=161 eyes), CDVA was -0.01 ± 0.07 logMAR at one-month. Monocular UIVA was 0.22 ± 0.14 logMAR, DCIVA was 0.24 ± 0.12 logMAR, and absolute IOL rotation was 1.02 ± 1.21°. Residual astigmatism was very low (<0.01D) and consistently low across T2 to T6 IOLs. A T3 to T6 sub-analysis (n=64 eyes) found CDVA of -0.01 ± 0.07 logMAR, UIVA of 0.20 ± 0.14 logMAR, DCIVA of 0.23 ± 0.13 logMAR, and absolute rotation of 1.08 ± 1.26°. For all eyes, 1 serious ocular AE, cystoid macular edema, was identified. No serious non-ocular AEs, device deficiencies, or posterior capsular opacification were observed.</p><p><strong>Conclusion: </strong>The Clareon aspheric monofocal toric IOL showed excellent improvement in distance visual acuity and treatment of astigmatism, with functional intermediate visual acuity and minimal rotation.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2945-2953"},"PeriodicalIF":0.0,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12382968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Oxymetazoline 0.1% in Acquired Blepharoptosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.","authors":"Razan O Bawazir, Jumanah T Qedair, Ziad M Bukhari, Orjwan S Badghaish, Rahaf A Hubayni, Ali S Alsudais, Mohammed F Qutub","doi":"10.2147/OPTH.S529633","DOIUrl":"10.2147/OPTH.S529633","url":null,"abstract":"<p><strong>Purpose: </strong>Abnormal eyelid drooping is a defining feature of blepharoptosis, a disorder that can affect the superior vision field. The standard of care is surgical intervention but may be associated with complications. There is emerging evidence that the direct-acting α-adrenergic agonist ophthalmic solution, oxymetazoline, is effective for blepharoptosis. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of oxymetazoline in the management of blepharoptosis.</p><p><strong>Patients and methods: </strong>A total of five databases were searched. The inclusion was limited only to randomized controlled trials (RCTs) that evaluated the efficacy of oxymetazoline versus placebo. The efficacy endpoint was the mean change in the marginal reflex distance 1 (MRD 1) from baseline. The safety endpoints were mortality and adverse events (AEs). The weighted mean difference (WMD) was implemented for continuous outcomes. For risk of bias assessment, the Revised Cochrane risk of bias tool for randomized trials was used.</p><p><strong>Results: </strong>4 RCTs (n = 448) met the eligibility criteria. The meta-analysis yielded a statistically significant higher difference in the WMD in the oxymetazoline group [0.65 mm (95% CI: 0.44 mm to 0.86 mm)] compared to the placebo group [0.26 mm (95% CI: 0.30 mm to 0.48 mm) [p=0.012]. There were no statistically significant differences between the oxymetazoline group [1.2% (95% CI: 0.4-3.6%)] and the placebo group [1.6% (95% CI: 0.5-5.3%), p = 0.73] in terms of serious adverse events.</p><p><strong>Conclusion: </strong>Oxymetazoline is an effective and safe medication in the management of acquired blepharoptosis.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2955-2964"},"PeriodicalIF":0.0,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12383003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Structural Effects of Novel Endoscopic Cyclophotocoagulation versus Standard Endoscopic and Transscleral Cyclophotocoagulation.","authors":"Haider Sarwar, Nicholas Tan, Saif Aldeen Alryalat, Cara Elise Capitena Young, Leonard K Seibold, Malik Y Kahook","doi":"10.2147/OPTH.S542095","DOIUrl":"10.2147/OPTH.S542095","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the acute structural changes of standard endoscopic cyclophotocoagulation (ECP), a novel ECP device (Leos™), and transscleral cyclophotocoagulation (TCP) on the ciliary processes and surrounding structures in human cadaveric eyes using scanning electron microscopy (SEM).</p><p><strong>Patients and methods: </strong>Three human cadaveric eyes were treated with standard ECP, Leos ECP, or TCP. Untreated areas served as controls. Tissues were prepared for SEM to evaluate microarchitectural changes in the ciliary processes and adjacent structures.</p><p><strong>Results: </strong>SEM imaging revealed that both standard and Leos ECP resulted in blunting of the ciliary processes without injury to collateral tissues. In contrast, TCP-treated tissues showed significant structural disorganization extending to the iris and pars plana.</p><p><strong>Conclusion: </strong>In this study, we demonstrate that both standard and novel Leos ECP techniques produce significantly less structural disruption to the ciliary processes compared to TCP. The Leos ECP system, with its enhanced imaging and automation features, may offer more clinical value through ease-of-use and improved consistency while still generating similar tissue effects to standard ECP. Additionally, these findings further validate the more targeted approach that ECP offers compared to TCP. However, no clinical outcomes were evaluated in this study, and further investigation is needed to determine how these findings translate to patient care.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2939-2943"},"PeriodicalIF":0.0,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12379975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}